Neoadjuvant immunotherapy using nivolumab prior to early lung cancer surgery is safe and feasible

Adapted from Press release by European Society for Medical OncologyNeoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.Background"Until now nivolumab and the other anti-PD-1 and anti-PD-L1 drug studies have only been reported in metastatic or advanced lung … Continue reading Neoadjuvant immunotherapy using nivolumab prior to early lung cancer surgery is safe and feasible